We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Ocugen (OCGN - Free Report) . Shares have added about 2.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Ocugen due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Ocugen, Inc. before we dive into how investors and analysts have reacted as of late.
Key Highlights
• Revenue: negative $0.2M in Q4 FY2025 vs. $0.8M in Q4 FY2024. • GAAP EPS (diluted): loss $0.06 in Q4 FY2025 vs. loss $0.05 in Q4 FY2024 • R&D: $10.7M in Q4 FY2025 vs. $8.3M in Q4 FY2024 • G&A: $6.1M in Q4 FY2025 vs. $6.3M in Q4 FY2024. • Total operating expenses: $17.0M vs. $13.8M. • Net loss: $17.7M vs. $13.9M.
Revenues and EPS
Fourth-quarter fiscal 2025 revenues were a negative $0.2 million, caused by lower collaboration revenue recognition year over year. The Zacks Consensus Estimate was $2 million.
Adjusted loss was 6 cents per share, in line with the Zacks Consensus Estimate. The wider GAAP loss reflected higher operating expenses and increased interest/other expense.
Operating Expenses and Profits
Total operating expenses rose 15% YoY, widening loss from operations and net loss. R&D increased 29% as late-stage programs and manufacturing readiness advanced; G&A remained roughly flat.
Program Execution and Management Commentary
Management emphasized 2026 catalysts and confirmed timelines:
• OCU400 (RP): Phase III liMeliGhT enrollment completed. Rolling BLA targeted Q3 2026; topline Q1 2027. Process validation and CMC activities progressing; brand planning underway. • OCU410ST (Stargardt): Phase II/III enrollment expected to be completed in Q1 2026; topline Q2 2027 and a 2027 BLA. • OCU410 (GA): Positive preliminary 12-month phase II signals reported; full Phase II data expected March 2026 and Phase III planned in 2026. • OCU200: Phase I enrollment targeted to complete Q1 2026 • OCU500: NIAID intends to initiate phase I in Q2 2026. (10-K, Q4_2025)
Balance Sheet and Liquidity
Year-end cash was $18.9M. Subsequent gross proceeds of $22.5 million (January 2026) fund operations into fourth-quarter 2026; full exercise of $30 million of outstanding warrants could extend runway into second-quarter 2027. Total debt remained largely stable; stockholders' equity was in deficit.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates revision.
The consensus estimate has shifted 17.95% due to these changes.
VGM Scores
At this time, Ocugen has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock has a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Interestingly, Ocugen has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Ocugen is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, TG Therapeutics (TGTX - Free Report) , a stock from the same industry, has gained 15.5%. The company reported its results for the quarter ended December 2025 more than a month ago.
TG Therapeutics reported revenues of $192.57 million in the last reported quarter, representing a year-over-year change of +78%. EPS of $0.14 for the same period compares with $0.15 a year ago.
TG Therapeutics is expected to post earnings of $0.25 per share for the current quarter, representing a year-over-year change of +733.3%. Over the last 30 days, the Zacks Consensus Estimate has changed +9.1%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for TG Therapeutics. Also, the stock has a VGM Score of F.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Ocugen (OCGN - Free Report) . Shares have added about 2.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Ocugen due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Ocugen, Inc. before we dive into how investors and analysts have reacted as of late.
Key Highlights
• Revenue: negative $0.2M in Q4 FY2025 vs. $0.8M in Q4 FY2024.
• GAAP EPS (diluted): loss $0.06 in Q4 FY2025 vs. loss $0.05 in Q4 FY2024
• R&D: $10.7M in Q4 FY2025 vs. $8.3M in Q4 FY2024
• G&A: $6.1M in Q4 FY2025 vs. $6.3M in Q4 FY2024.
• Total operating expenses: $17.0M vs. $13.8M.
• Net loss: $17.7M vs. $13.9M.
Revenues and EPS
Fourth-quarter fiscal 2025 revenues were a negative $0.2 million, caused by lower collaboration revenue recognition year over year. The Zacks Consensus Estimate was $2 million.
Adjusted loss was 6 cents per share, in line with the Zacks Consensus Estimate. The wider GAAP loss reflected higher operating expenses and increased interest/other expense.
Operating Expenses and Profits
Total operating expenses rose 15% YoY, widening loss from operations and net loss. R&D increased 29% as late-stage programs and manufacturing readiness advanced; G&A remained roughly flat.
Program Execution and Management Commentary
Management emphasized 2026 catalysts and confirmed timelines:
• OCU400 (RP): Phase III liMeliGhT enrollment completed. Rolling BLA targeted Q3 2026; topline Q1 2027. Process validation and CMC activities progressing; brand planning underway.
• OCU410ST (Stargardt): Phase II/III enrollment expected to be completed in Q1 2026; topline Q2 2027 and a 2027 BLA.
• OCU410 (GA): Positive preliminary 12-month phase II signals reported; full Phase II data expected March 2026 and Phase III planned in 2026.
• OCU200: Phase I enrollment targeted to complete Q1 2026
• OCU500: NIAID intends to initiate phase I in Q2 2026. (10-K, Q4_2025)
Balance Sheet and Liquidity
Year-end cash was $18.9M. Subsequent gross proceeds of $22.5 million (January 2026) fund operations into fourth-quarter 2026; full exercise of $30 million of outstanding warrants could extend runway into second-quarter 2027. Total debt remained largely stable; stockholders' equity was in deficit.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates revision.
The consensus estimate has shifted 17.95% due to these changes.
VGM Scores
At this time, Ocugen has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock has a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Interestingly, Ocugen has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Ocugen is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, TG Therapeutics (TGTX - Free Report) , a stock from the same industry, has gained 15.5%. The company reported its results for the quarter ended December 2025 more than a month ago.
TG Therapeutics reported revenues of $192.57 million in the last reported quarter, representing a year-over-year change of +78%. EPS of $0.14 for the same period compares with $0.15 a year ago.
TG Therapeutics is expected to post earnings of $0.25 per share for the current quarter, representing a year-over-year change of +733.3%. Over the last 30 days, the Zacks Consensus Estimate has changed +9.1%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for TG Therapeutics. Also, the stock has a VGM Score of F.